Table 2 Clinical trials combining epigenetic targeting agents and immune checkpoint inhibitors
From: Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Epigenetic targeting agents | Immune checkpoint inhibitors | Conditions and trial ID |
|---|---|---|
DNMTi | ||
 Azacytidine | Pembrolizumab (anti-PD1) | CRC (NCT02260440, NCT02512172), NSCLC, microsatellite-stable CRC, HNSCC, urothelial carcinoma and melanoma (NCT02959437), AML (NCT02845297, NCT04284787, NCT03769532), NSCLC (NCT02546986), myelodysplastic syndrome (MDS) (NCT03094637), melanoma (NCT02816021), PDAC (NCT03264404), platinum-resistant ovarian cancer (NCT02900560), relapsed/refractory Hodgkin lymphoma (NCT05355051) |
| Â | Nivolumab (anti-PD1) | AML (NCT02397720, NCT03825367, NCT04913922), NSCLC (NCT01928576), MDS (NCT02530463) osteosarcoma (NCT03628209), hodgkin lymphoma (NCT05162976), HNSCC (NCT05317000) |
| Â | Durvalumab (anti-PD-L1) | MDS (NCT02281084, NCT02117219, NCT02775903), AML (NCT02775903), peripheral T-cell lymphoma (NCT03161223), NSCLC (NCT02250326), pancreatic cancer (NCT04257448), microsatellite-stable CRC, ovarian cancer and estrogen receptor-positive and HER2-negative breast cancer (NCT02811497) |
| Â | Camrelizumab (anti-PD1) | AML (NCT05772273), peripheral T-Cell lymphoma (NCT05559008) |
| Â | Atezolizumab (anti-PD-L1) | MDS (NCT02508870) |
| Â | Avelumab (anti-PD-L1) | AML (NCT03390296) |
| Â | Spartalizumab (anti-PD1) | MDS/AML (NCT03066648) |
| Â | Tremelimumab (anti-CTLA4) | MDS (NCT02117219) |
| Â | Ipilimumab (anti-CTLA4) | MDS (NCT02530463), AML(NCT02397720) |
| Â | PF-04518600 (anti-OX40) | AML (NCT03390296) |
 Decitabine | Pembrolizumab | AML (NCT02996474, NCT03969446), MDS (NCT03969446), peripheral T-cell lymphoma/cutaneous T-cell lymphoma (NCT03240211), CNS solid tumors and lymphomas (NCT03445858), NSCLC (NCT03233724), locally advanced HER2-negative breast cancer (NCT02957968), metastatic triple-negative breast cancer (NCT05673200) |
| Â | Nivolumab | Mucosal melanoma (NCT05089370), AML (NCT04277442), NSCLC (NCT02664181), MDS/AML (NCT02664181) |
| Â | Durvalumab | head and neck cancer (NCT03019003), |
| Â | Camrelizumab | Hodgkin lymphoma (NCT04510610, NCT03250962, NCT04514081, NCT04233294), primary mediastinal large B-cell lymphoma (NCT03346642), AML(NCT04353479) |
| Â | Spartalizumab | MDS (NCT05201066), MDS/AML (NCT03066648) |
| Â | Ipilimumab | Relapsed or refractory myelodysplastic syndrome or AML (NCT02890329) |
 Guadecitabine | Pembrolizumab | Lung cancer (NCT03220477), NSCLC/castration-resistant prostatic cancer (NCT02998567), ovarian, primary peritoneal or fallopian tube cancer (NCT02901899) |
| Â | Nivolumab | Melanoma, NSCLC (NCT04250246) |
| Â | Durvalumab | Advanced kidney cancer (NCT03308396), extensive-stage small cell lung cancer (NCT03085849), hepatocellular carcinoma, gallbladder cancer, pancreatic cancer, intrahepatic cholangiocarcinoma (NCT03257761) |
| Â | Atezolizumab | Chronic myelomonocytic leukemia, MDS and AML (NCT02935361), AML (NCT02892318), ovarian, fallopian tube, or primary peritoneal cancer (NCT03206047), urothelial carcinoma (NCT03179943) |
| Â | Tremelimumab | Extensive-stage small cell lung cancer (NCT03085849) |
| Â | Ipilimumab | Melanoma (NCT02608437), melanoma/NSCLC (NCT04250246) |
HDACi | ||
 Vorinostat | Pembrolizumab | HNSCC or salivary gland cancer (NCT02538510), NSCLC (NCT02638090), renal or urothelial cell carcinoma (NCT02619253), glioblastoma (NCT03426891), diffuse large B-cell lymphoma, follicular lymphoma or Hodgkin lymphoma (NCT03150329), squamous cell carcinoma (NCT04357873), breast cancer (NCT04190056) |
 Entinostat | Pembrolizumab | MDS (NCT02936752), advanced solid tumors (NCT02909452), lymphoma (NCT03179930), NSCLC, melanoma and CRC (NCT02437136), melanoma (NCT03765229), uveal melanoma (NCT02697630), bladder cancer (NCT03978624) |
| Â | Nivolumab | CNS tumor, solid tumor (NCT03838042), renal cell carcinoma (NCT03552380), HER2-negative breast cancer (NCT02453620), non-small cell lung cancer (NCT01928576), cholangiocarcinoma or PDAC (NCT03250273) |
| Â | Ipilimumab | HER2-negative breast cancer (NCT02453620), renal cell carcinoma (NCT03552380) |
| Â | Atezolizumab | Triple-negative breast cancer (NCT02708680), lung cancer (NCT04631029), hormone receptor-positive, HER2-negative breast cancer (NCT03280563), renal cell carcinoma (NCT03024437) |
| Â | Avelumab | Ovarian, peritoneal and fallopian tube cancer (NCT02915523) |
 Panobinostat | Ipilimumab | Melanoma (NCT02032810) |
| Â | Nivolumab | Triple-negative breast cancer (NCT02393794) |
| Â | Durvalumab | Lymphoma (NCT03161223) |
 Mocetinostat | Pembrolizumab | Lung cancer (NCT03220477) |
| Â | Nivolumab | NSCLC (NCT02954991) |
 ACY-241 | Nivolumab | NSCLC (NCT02635061), Melanoma (NCT02935790) |
| Â | Ipilimumab | Melanoma (NCT02935790) |
 Valproic acid | Avelumab | Virus-associated cancers (NCT03357757) |
 inostamustine | Nivolumab | Advanced melanoma (NCT03903458) |
 Chidamide | Nivolumab | Melanoma, renal cell carcinoma, NSCLC (NCT02718066), advanced melanoma (NCT04674683) |
| Â | Pembrolizumab | NSCLC (NCT05141357) |
 Abexinostat | Pembrolizumab | Solid tumors (NCT03590054) |
 Domatinostat | Avelumab | Merkel cell carcinoma (NCT04393753), Gastrointestinal cancers (NCT03812796) |
| Â | Nivolumab and ipilimumab | Melanoma (NCT04133948) |
 Nanatinostat | Pembrolizumab | EBV-positive solid tumors (NCT05166577) |
BET inhibitor | ||
 BMS-986158 | Nivolumab | Selected advanced tumors (NCT02419417) |
EZH2 inhibitor | ||
 Tazemetostat | Pembrolizumab | Urothelial carcinoma (NCT03854474), HNSCC (NCT04624113) |
| Â | Atezolizumab | Follicular lymphoma and diffuse large B-cell lymphoma (NCT02220842) |
| Â | Nivolumab and ipilimumab | Malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, and chordoma (NCT05407441) |
| Â | Durvalumab | Advanced solid tumors (NCT04705818) |
 CPI-1205 | Ipilimumab | Advanced solid tumors (NCT03525795) |
KDM1A inhibitor | ||
 IMG-7289 | Atezolizumab | Extensive-stage small cell lung cancer (NCT05191797) |
